About me
Eamonn Nolan is a seasoned corporate communications and investor relations leader with a strong track record in the pharmaceutical, biotech, and healthcare non-profit sectors. He specializes in advising C-suite executives, enhancing corporate reputation, articulating compelling value propositions, and developing innovative programs that drive business success.
Currently, Eamonn serves as Senior Director of Corporate Communications at Agios Pharmaceuticals, a Boston-based biotech company focused on developing and commercializing treatments for rare diseases. Reporting to the Chief Financial Officer, he oversees all external communications, ensuring the company’s mission, progress, and achievements are effectively conveyed to key stakeholders.
Prior to Agios, Eamonn was Senior Director of Corporate Communications and Investor Relations at MorphoSys, where he played a key role in shaping the company’s public image and financial messaging. During his tenure, he led the company’s first strategic rebranding in over 30 years, managed corporate, digital, social media, financial, and CEO communications, and oversaw the announcement of positive Phase 3 results for pelabresib, the company’s lead asset. He also spearheaded communications for a successful capital raise and played a central role in managing messaging and stakeholder engagement throughout MorphoSys’ €2.7 billion acquisition by Novartis. In this capacity, he worked closely with senior leaders, integration teams, investment bankers, consultants, and legal advisors, navigating the complexities of a dual U.S./Germany listing.
Before MorphoSys, Eamonn was a member of Pfizer’s Global Media Relations team, serving as a spokesperson for the company’s commercial organization across six therapeutic areas and more than 500 medicines. He played a key role in shaping the public narrative around the Pfizer-BioNTech COVID-19 vaccine, securing high-impact media placements in The Wall Street Journal, The New York Times, USA TODAY, and The Washington Post. Previously, he managed corporate and internal communications for Pfizer Oncology, led product communications for Pfizer’s breast and prostate cancer franchises, and oversaw global and U.S. cancer patient engagement programs.
Eamonn also brings agency experience, having worked at dna Communications (part of the IPG network) and Ruder Finn, where he led award-winning communications programs for major clients, including the Boehringer Ingelheim/Eli Lilly and Company alliance, Celgene (a BMS company), and Novartis.
A graduate of Providence College, Eamonn resides in New York, NY, and actively volunteers with Habitat
